Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.36 |
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
| ▸ | DEPTOR | Q8TB45 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710048 | 0.98 | TDP1 (0.43) | TDP1TSHRCYP1A1CYP1B1NOX1 | |
| Formaldehyde SCHEMBL11097624 | 0.91 | TSHR (0.39) | TDP1TSHRCYP1A1CYP1B1NOX1 | |
| SCHEMBL20489080 | 0.74 | MAPT (0.38) | TSHRCYP1A1ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL28454114 | 0.74 | ALDH1A1 (0.37) | TDP1ALDH1A1L3MBTL1ALOX12MAPK1 | |
| SCHEMBL9055960 | 0.68 | TDP1 (0.67) | TDP1TSHRCYP1A1CYP1B1NOX1 | |
| Hydrochloric Acid SCHEMBL27882982 | 0.67 | TDP1 (0.46) | TDP1TSHRCYP1A1CYP1B1NOX1 | |
| SCHEMBL20489078 | 0.67 | RAB9A (0.38) | TDP1ALDH1A1HSD17B10L3MBTL1ALOX15 | |
| SCHEMBL28173379 | 0.64 | — | — | |
| SCHEMBL28562018 | 0.64 | LTA4H (0.35) | TSHR | |
| SCHEMBL4572714 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113425853-B | Glutathione-modified brain-targeted zinc oxide quantum dot gene transport carrier and preparation method thereof | 华南师范大学 | 2023-05-05 | — | — | CN | claimed |
| CN-114160066-A | Equipment and method for producing diazotized phenylhydrazine hydrochloride based on microreactor | 启东亚太药业有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-113425853-A | Glutathione-modified brain-targeted gene transport vector of zinc oxide quantum dots and preparation method thereof | 华南师范大学 | 2021-09-24 | — | — | CN | claimed |
| CN-106310256-B | Construction method and application of cellulose membrane loaded with breast cancer targeted magnetic nano-drug | 华南师范大学 | 2020-01-14 | — | — | CN | claimed |
| EP-3838927-B1 | CROSS-LINKED HYALURONIC ACID AND USE THEREOF FOR LIMITING THE RECURRENCE OF A TUMOUR | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-10-09 | — | — | EP | disclosed |
| CN-113425853-B | Glutathione-modified brain-targeted zinc oxide quantum dot gene transport carrier and preparation method thereof | 华南师范大学 | 2023-05-05 | — | — | CN | disclosed |
| CN-109331186-B | Gold nanoparticle compound modified by liposome and application thereof in treating Parkinson's disease | 华南师范大学 | 2022-04-05 | — | — | CN | disclosed |
| CN-114160066-A | Equipment and method for producing diazotized phenylhydrazine hydrochloride based on microreactor | 启东亚太药业有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-113425853-A | Glutathione-modified brain-targeted gene transport vector of zinc oxide quantum dots and preparation method thereof | 华南师范大学 | 2021-09-24 | — | — | CN | disclosed |
| CN-106310256-B | Construction method and application of cellulose membrane loaded with breast cancer targeted magnetic nano-drug | 华南师范大学 | 2020-01-14 | — | — | CN | disclosed |
| US-20190029960-A1 | Therapeutic Nanoparticles Having EGFR Ligands and Methods of Making and Using Same | PFIZER INC. (US) | 2019-01-31 | — | — | US | disclosed |
| EP-3413917-A1 | THERAPEUTIC NANOPARTICLES HAVING EGFR LIGANDS AND METHODS OF MAKING AND USING SAME | Pfizer Inc (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20140120069-A1 | Amphoteric Materials Based on Crosslinked Hyaluronic Acid, Method of Preparation Thereof, Materials Containing Entrapped Active Agents, Method of Preparation Thereof, and Use of Said Materials | CONTIPRO BIOTECH S.R.O. (CZ) | 2014-05-01 | — | — | US | disclosed |
| EP-2702079-A1 | AMPHOTERIC MATERIALS BASED ON CROSSLINKED HYALURONIC ACID, METHOD OF PREPARATION THEREOF, MATERIALS CONTAINING ENTRAPPED ACTIVE AGENTS, METHOD OF PREPARATION THEREOF, AND USE OF SAID MATERIALS | Contipro Biotech s.r.o. (CZ) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012146218-A1 | AMPHOTERIC MATERIALS BASED ON CROSSLINKED HYALURONIC ACID, METHOD OF PREPARATION THEREOF, MATERIALS CONTAINING ENTRAPPED ACTIVE AGENTS, METHOD OF PREPARATION THEREOF, AND USE OF SAID MATERIALS | CONTIPRO BIOTECH S.R.O. (CZ) | 2012-11-01 | — | — | WO | disclosed |
| US-20120178165-A1 | POLYMERIC COATINGS AND METHODS FOR FORMING THEM | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2012-07-12 | — | — | US | disclosed |
| US-8124188-B2 | Polymeric coatings and methods for forming them | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2012-02-28 | — | — | US | disclosed |
| EP-2052045-A1 | POLYMERIC COATINGS AND METHODS FOR FORMING THEM | Commonwealth Scientific and Industrial Research Organisation (AU) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008019450-A1 | POLYMERIC COATINGS AND METHODS FOR FORMING THEM | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045686-A1 | POLYMERIC COATINGS AND METHODS FOR FORMING THEM | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190029960-A1 | Therapeutic Nanoparticles Having EGFR Ligands and Methods of Making and Using Same | EGFR, ERBB3, ERBB2 | PTGS2 3606/4885PTGS1 3173/4885SLC6A2 4231/4885 |
| US-20140120069-A1 | Amphoteric Materials Based on Crosslinked Hyaluronic Acid, Method of Preparation Thereof, Materials Containing Entrapped Active Agents, Method of Preparation Thereof, and Use of Said Materials | CD44, HDGF, FGF2 | PTGS2 262/4885PTGS1 109/4885SLC6A2 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.